RT Journal Article
SR Electronic
T1 Milk of cow and goat, immunized by recombinant protein vaccine ZF-UZ-VAC2001(Zifivax), contains neutralizing antibodies against SARS-CoV-2 and remains active after standard milk pasteurization
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.02.14.480298
DO 10.1101/2022.02.14.480298
A1 Victoria Garib
A1 Stefani Katsamaki
A1 Shahlo Turdikulova
A1 Yuliya Levitskaya
A1 Nodira Zahidova
A1 Galina Bus
A1 Kristina Karamova
A1 Manona Rakhmedova
A1 Nigora Magbulova
A1 Alexander Bruhov
A1 Firuz Y. Garib
A1 Ibrokhim Y. Abdurakhmonov
YR 2022
UL http://biorxiv.org/content/early/2022/02/15/2022.02.14.480298.abstract
AB Here we report the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cow and goat using recombinant protein human vaccine, ZF-UZ-VAC2001. In the period of two weeks after first vaccination, we detected the neutralizing antibodies against coronavirus in the blood serum of vaccinated animals. The neutralizing activity, in its peak on the 21st days after receiving the third dose (77th day from first dose), was effective in Neutralization Test using a live SARS-CoV-2 in Vero E6 cells, even after 120-fold serum titration. Colostrum of the first day after 3rd dose vaccinated cow after calving had a greater activity to neutralize the SARS-CoV-2 compared to colostrum of subsequent three days (4.080 µg/ml vs 2.106, 1.960 and 1.126 µg/ml), goat milk (1,486 µg/ml), and cow milk (0.222 µg/ml) in MAGLUMI® SARS-CoV-2 neutralizing antibody competitive chemiluminescence immunoassay. We observed a positive correlation of receptor-binding domain (RBD)-specific IgG antibodies between the serum of actively immunized cow and milk-feeding calf during the entire course of vaccination (r = 0.95, p = 0.027). We showed an optimal regime for immune milk pasteurization at 62.5°C for 30 min, which retained specific neutralizing activity to SARS-CoV-2, potentially useful for passive immunization against coronavirus infection threats.Competing Interest StatementThe authors declare that the study concept and results are filed for patenting at the Intellectual Property Agency under the Ministry of Justice of the Republic of Uzbekistan with pending application № IAP 2021 0365.ACE2angiotensin-converting enzyme 2COVID-19coronavirus diseaseELISAenzyme-linked immunosorbent assayHRPhorseradish peroxidaseIgG, IgA, IgMimmunoglobulin G, A, MnAbsneutralizing antibodiesNTNeutralization testODoptical densityRBDreceptor-binding domainSspike proteinS1spike protein receptor-binding subunitSARSsevere acute respiratory syndromeVOCvariants of concernCLIAchemiluminescence immunoassayEUAemergency use approvalZF-UZ-VAC2001Zhifei (ZF) – Uzbekistan (UZ) –Vaccine (VAC) project started in January of 2020 (20/01)